Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082810 · ClinicalTrials.gov registry record · Phase 2
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00082810: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00082810 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00082810, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving tipifarnib together with fulvestrant works as second-line therapy in treating postmenopausal women with hormone receptor-positive inoperable locally advanced or metastatic breast cancer that has progressed after previous first-line endocrine therapy. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen. Combining tipifarnib with fulvestrant may kill tumor cells that did not respond to first-line therapy.
Interventions
- DRUG fulvestrant
- DRUG tipifarnib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2004-03 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082810
The ClinicalTrials.gov registry entry for NCT00082810 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fulvestrant is the first listed.
NCT00082810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00082810 about?
NCT00082810 is a clinical study titled "Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer". This phase II trial is studying how well giving tipifarnib together with fulvestrant works as second-line therapy in treating postmenopausal women with hormone receptor-positive inoperable locally advanced or metastatic breast cancer that has progressed after previous first-line endocrine therapy. T...
What is the current status of trial NCT00082810?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2004-03. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00082810?
The interventions under investigation include: fulvestrant (DRUG), tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00082810?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.